AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14651992 — intervention group
Group type: EXPERIMENTAL
Intervention: Both trained and sedentary subjects
Number of subjects: 0
Study 10826412 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (300 mg/day)
Number of subjects: 142
Study 10826412 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 142
Study 8877027 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEpo) 200 u kg‐1
Number of subjects: 30
Study 8877027 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 1499473 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 U/kg body wt NPH insulin
Number of subjects: 16
Study 1499473 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g/day metformin
Number of subjects: 16
Study 1499473 — intervention group
Group type: COMPARATOR
Intervention: glyburide alone
Number of subjects: 16
Study 6209324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollen extract
Number of subjects: 0
Study 6209324 — intervention group
Group type: COMPARATOR
Intervention: Buffer
Number of subjects: 0
Study 30080730 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection (LAP)
Number of subjects: 462
Study 30080730 — intervention group
Group type: COMPARATOR
Intervention: Open resection (OPEN)
Number of subjects: 462
Study 29537981 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic normoglycemia
Number of subjects: 1439
Study 29537981 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic management
Number of subjects: 1439
Study 25887817 — intervention group
Group type: EXPERIMENTAL
Intervention: Blade Plate (BPL)
Number of subjects: 734
Study 25887817 — intervention group
Group type: COMPARATOR
Intervention: Screw-side Plate (SSP)
Number of subjects: 734
Study 24667134 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol antioxidant (PA)
Number of subjects: 12
Study 24667134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 12
Study 21901262 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser microscopy (CLM)
Number of subjects: 21
Study 20973744 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (lutein 3.2 mg, L-glutathione 5 mg, vitamin E 15 IU, vitamin C 150 mg, zinc 40 mg, copper 2 mg, selenium 40 mcg, manganese 5 mg) administered once a day for 3 months.
Number of subjects: 15
Study 20973744 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no antioxidant supplementation).
Number of subjects: 15
Study 17381555 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache patients (n=70)
Number of subjects: 210
Study 17381555 — intervention group
Group type: EXPERIMENTAL
Intervention: RAP patients (n=70)
Number of subjects: 210
Study 17381555 — intervention group
Group type: COMPARATOR
Intervention: Controls (n=70)
Number of subjects: 210
Study 17381555 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs (subgroup of headache patients)
Number of subjects: 210
Study 15694064 — intervention group
Group type: COMPARATOR
Intervention: Computerised referral guidelines for GPs
Number of subjects: 289
Study 15694064 — intervention group
Group type: COMPARATOR
Intervention: Nurse counsellor intervention
Number of subjects: 289
Study 12059890 — intervention group
Group type: EXPERIMENTAL
Intervention: Inguinal field block (IFB) with ropivacaine (50-60 ml, 5 mg/ml) before surgery
Number of subjects: 60
Study 12059890 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with wound infiltration postoperatively
Number of subjects: 60
Study 10204872 — intervention group
Group type: EXPERIMENTAL
Intervention: Space flight (17 day Spacelab mission)
Number of subjects: 4
Study 10204872 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 subjects)
Number of subjects: 4
Study 7779538 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (AOT)
Number of subjects: 20
Study 7779538 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 7779538 — intervention group
Group type: COMPARATOR
Intervention: Conditioning therapy
Number of subjects: 20
Study 2277155 — intervention group
Group type: EXPERIMENTAL
Intervention: XR‐Ionomer (Kerr)
Number of subjects: 40
Study 2277155 — intervention group
Group type: EXPERIMENTAL
Intervention: XR‐Ionomer with polyacrylic acid (PAA) pretreatment (Kerr)
Number of subjects: 40
Study 2277155 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrabond (3M)
Number of subjects: 40
Study 2277155 — intervention group
Group type: COMPARATOR
Intervention: Ketac‐Bond (ESPE‐Premier)
Number of subjects: 40
Study 6446052 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 200
Study 6446052 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomy
Number of subjects: 200
Study 30741803 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective induction of labor
Number of subjects: 0
Study 30741803 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study 28917363 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (Buddhist music for 30 minutes before sleep)
Number of subjects: 71
Study 28917363 — intervention group
Group type: EXPERIMENTAL
Intervention: Music video intervention (Buddhist music videos for 30 minutes before sleep)
Number of subjects: 71
Study 28917363 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 71
Study 26914986 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + 10% E. officinalis gel application
Number of subjects: 46
Study 26914986 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo gel
Number of subjects: 46
Study 24097277 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous transurethral PVBT/PVP
Number of subjects: 62
Study 24097277 — intervention group
Group type: COMPARATOR
Intervention: PVBT alone
Number of subjects: 62
Study 21769657 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutually violent group (n=81)
Number of subjects: 519
Study 21769657 — intervention group
Group type: EXPERIMENTAL
Intervention: Victims-only group (n=39)
Number of subjects: 519
Study 21769657 — intervention group
Group type: COMPARATOR
Intervention: Non-violent group (n=367)
Number of subjects: 519
Study 21769657 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetrator-only group (n=32)
Number of subjects: 519
Study 19545427 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 POUNDS gift voucher (incentive group)
Number of subjects: 2144
Study 19545427 — intervention group
Group type: COMPARATOR
Intervention: No gift voucher (no incentive group)
Number of subjects: 2144
Study 17514666 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic AAA screening
Number of subjects: 6040
Study 17514666 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 6040
Study 15743276 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT intervention (n=906)
Number of subjects: 1801
Study 15743276 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=895)
Number of subjects: 1801
Study 12085257 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16 seropositive individuals
Number of subjects: 28
Study 12085257 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 18 seropositive individuals
Number of subjects: 28
Study 12085257 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16 seropositive individuals above age 45
Number of subjects: 28
Study 12085257 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16 seropositive individuals with lag time < 10 years
Number of subjects: 28
Study 9616313 — intervention group
Group type: COMPARATOR
Intervention: R093877 1 mg
Number of subjects: 17
Study 9616313 — intervention group
Group type: COMPARATOR
Intervention: R093877 2 mg
Number of subjects: 17
Study 9616313 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 17
Study 8129159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 1 mg
Number of subjects: 1000
Study 8129159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 1000
Study 8129159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 1000
Study 8129159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 2508213 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms twice daily
Number of subjects: 10
Study 2508213 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 7 micrograms twice daily
Number of subjects: 10
Study 2508213 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 500 mg four times a day
Number of subjects: 10
Study 2508213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31769106 — intervention group
Group type: EXPERIMENTAL
Intervention: Bony nasopharynx depth
Number of subjects: 200
Study 31769106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal tonsil depth
Number of subjects: 200
Study 31769106 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoid-nasopharyngeal ratio (ANR)
Number of subjects: 200
Study 30103299 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep heating therapy (DHT) via MF diathermy (450 KHz)
Number of subjects: 49
Study 30103299 — intervention group
Group type: COMPARATOR
Intervention: Superficial heating therapy (SHT) via electric resistance
Number of subjects: 49
Study 28338369 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich tuna fish oil (560mg DHA / 140mg EPA, 2 × 1g/day for 8 weeks)
Number of subjects: 26
Study 28338369 — intervention group
Group type: COMPARATOR
Intervention: Control (soy oil, 2 × 1g/day for 8 weeks)
Number of subjects: 26
Study 28338369 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich tuna fish oil
Number of subjects: 26
Study 28338369 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 26
Study 26379095 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery system
Number of subjects: 58
Study 26379095 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy
Number of subjects: 58
Study 22905853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 3254
Study 22905853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 3254
Study 22905853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3254
Study 22905853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg and 20 mg
Number of subjects: 3254
Study 21807638 — intervention group
Group type: EXPERIMENTAL
Intervention: Endopredict (EP) risk score
Number of subjects: 1702
Study 21807638 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Adjuvant!Online, quantitative ER, Ki67, and treatment with EP
Number of subjects: 1702
Study 21807638 — intervention group
Group type: EXPERIMENTAL
Intervention: EPclin risk score
Number of subjects: 1702
Study 18799004 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (maintaining glucose levels between 80 and 110 mg/dl)
Number of subjects: 504
Study 18799004 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin therapy (maintaining glucose levels between 180 and 200 mg/dl)
Number of subjects: 504
Study 18799004 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 504
Study 18799004 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin therapy
Number of subjects: 504
Study 16779924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections (IG) - 5 x 2 mL over 10 days
Number of subjects: 0
Study 16779924 — intervention group
Group type: COMPARATOR
Intervention: Oral tablets (OG) - one tablet daily for 30 days
Number of subjects: 0
Study 14579880 — intervention group
Group type: EXPERIMENTAL
Intervention: Premier MicroDose Porcelain Bonding/Optibond FL adhesive/Prodigy composite
Number of subjects: 40
Study 14579880 — intervention group
Group type: EXPERIMENTAL
Intervention: Premier MicroDose Porcelain Bonding/PQ1 adhesive/Amelogen composite
Number of subjects: 40
Study 14579880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultradent Porcelain Etch/Optibond FL adhesive/Prodigy composite
Number of subjects: 40
Study 14579880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultradent Porcelain Etch/PQ1 adhesive/Amelogen composite
Number of subjects: 40
Study 11434574 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 20
Study 11434574 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study 9600821 — intervention group
Group type: COMPARATOR
Intervention: Standard external beam pelvic irradiation (RT) 5000 cGy in 25 fractions
Number of subjects: 234
Study 9600821 — intervention group
Group type: EXPERIMENTAL
Intervention: RT with infusional IV 5‐FU 1g/m2 daily in the first and last 4 days of RT
Number of subjects: 234
Study 9600821 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hyperfractionated RT, 5280 cGy in 33 fractions, two fractions per day on the first and last 4 days of RT
Number of subjects: 234
Study 9600821 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hyperfractionated RT with concurrent 5‐FU
Number of subjects: 234
Study 9600821 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard RT and 5‐FU in stratum 1 (IB/IIA or medial parametrial IIB disease)
Number of subjects: 234
Study 7908693 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula supplemented with soy oil
Number of subjects: 0
Study 7908693 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula supplemented with soy and marine oils
Number of subjects: 0
Study 7908693 — intervention group
Group type: COMPARATOR
Intervention: Commercial ready-to-feed liquid formula (control)
Number of subjects: 0
Study 3048235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (1 mg/kg bodyweight) given 20 min prior to infusion of intravenous immunoglobulin.
Number of subjects: 10
Study 3048235 — intervention group
Group type: COMPARATOR
Intervention: No methylprednisolone prophylaxis given.
Number of subjects: 10
Study 31460865 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention with financial incentives (shopping vouchers) for cannabis abstinence over 12 once-weekly sessions, confirmed using urinalysis. Maximum value of vouchers: £240.
Number of subjects: 551
Study 31460865 — intervention group
Group type: COMPARATOR
Intervention: Control arm receiving treatment as usual only.
Number of subjects: 551
Study 28545506 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention for 10 weeks (subjective self-monitoring)
Number of subjects: 100
Study 28545506 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention for 10 weeks with Fitbit Zips (objective self-monitoring)
Number of subjects: 100
Study 28545506 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention control group
Number of subjects: 100
Study 25668262 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (10 g/d)
Number of subjects: 1741
Study 25668262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1741
Study 24107587 — intervention group
Group type: COMPARATOR
Intervention: DASH diet score quartiles
Number of subjects: 3215
Study 24107587 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet score quartiles
Number of subjects: 3215
Study 21590466 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented group (n = 144)
Number of subjects: 505
Study 21590466 — intervention group
Group type: COMPARATOR
Intervention: Nonstented group (n = 142)
Number of subjects: 505
Study 21590466 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (stented and nonstented)
Number of subjects: 505
Study 18082163 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 29
Study 18082163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 16571429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing training group (trained again to proficiency at 1 and 3 months)
Number of subjects: 18
Study 16571429 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 18
Study 12724020 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg/day
Number of subjects: 24
Study 12724020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10931081 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 IU/d sc human recombinant growth hormone for a mean of 14 weeks
Number of subjects: 50
Study 10931081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9294798 — intervention group
Group type: EXPERIMENTAL
Intervention: 95-degree DCS plate with dispersed screw configuration
Number of subjects: 12
Study 9294798 — intervention group
Group type: EXPERIMENTAL
Intervention: Genucephalic intramedullary nail with grouped screw configuration
Number of subjects: 12
Study 9294798 — intervention group
Group type: COMPARATOR
Intervention: Genucephalic intramedullary nail
Number of subjects: 12
Study 9294798 — intervention group
Group type: COMPARATOR
Intervention: 95-degree DCS plate
Number of subjects: 12
Study 30212555 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative package leaflets (drug facts box with/without reading instruction, narrative format with numbers)
Number of subjects: 397
Study 30212555 — intervention group
Group type: COMPARATOR
Intervention: Standard package leaflet
Number of subjects: 397
Study 27164847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual and alcohol risk reduction (NLITEN) condition
Number of subjects: 228
Study 27164847 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 228
Study 24297949 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene
Number of subjects: 1590
Study 24297949 — intervention group
Group type: EXPERIMENTAL
Intervention: ERG-positive patients
Number of subjects: 1590
Study 24297949 — intervention group
Group type: COMPARATOR
Intervention: ERG-negative patients
Number of subjects: 1590
Study 23166914 — intervention group
Group type: EXPERIMENTAL
Intervention: IPARZINE‐4A‐SKR topical agent
Number of subjects: 194
Study 23166914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 20088409 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA drink (1000 mg of GABA)
Number of subjects: 8
Study 20088409 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sports drink of 200 mL)
Number of subjects: 8
Study 16544102 — intervention group
Group type: EXPERIMENTAL
Intervention: PSTE (2.5 g)
Number of subjects: 7
Study 16544102 — intervention group
Group type: EXPERIMENTAL
Intervention: PSTA (2.5 g)
Number of subjects: 7
Study 16544102 — intervention group
Group type: COMPARATOR
Intervention: Control (no PSTE/PSTA)
Number of subjects: 7
Study 15131445 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs) in spine surgery
Number of subjects: 37
Study 15131445 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies reporting sample size calculation
Number of subjects: 37
Study 15131445 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies explicitly stating a primary outcome
Number of subjects: 37
Study 11337644 — intervention group
Group type: EXPERIMENTAL
Intervention: Hollow intubating introducer (HII) placed in trachea (Group T)
Number of subjects: 100
Study 11337644 — intervention group
Group type: COMPARATOR
Intervention: Hollow intubating introducer (HII) positioned in the esophagus (Group E)
Number of subjects: 100
Study 9042123 — intervention group
Group type: EXPERIMENTAL
Intervention: 80%:20% helium-oxygen gas mixture (HELIOX)
Number of subjects: 18
Study 9042123 — intervention group
Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 18
Study 7910127 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride 25 mg 3 times daily for 30 days
Number of subjects: 50
Study 7910127 — intervention group
Group type: COMPARATOR
Intervention: Domperidone 10 mg 3 times daily for 30 days
Number of subjects: 50
Study 3150693 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol plus lithium
Number of subjects: 36
Study 3150693 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol plus placebo
Number of subjects: 36
Study 31322799 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven self-calibration and reconstruction approach
Number of subjects: 29
Study 31322799 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach using iterative self-calibration and reconstruction with parallel imaging and compressed sensing
Number of subjects: 29
Study 30153265 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourced HIV intervention (multimedia HIV testing campaign, online HIV testing service, local testing promotion campaigns)
Number of subjects: 1381
Study 30153265 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourced HIV intervention
Number of subjects: 1381
Study 28213593 — intervention group
Group type: EXPERIMENTAL
Intervention: VVZ-149 with intravenous (IV) hydromorphone patient-controlled analgesia (PCA)
Number of subjects: 120
Study 28213593 — intervention group
Group type: COMPARATOR
Intervention: IV PCA alone (control)
Number of subjects: 120
Study 26179984 — intervention group
Group type: EXPERIMENTAL
Intervention: Retromuscular synthetic mesh (study group)
Number of subjects: 58
Study 26179984 — intervention group
Group type: COMPARATOR
Intervention: No mesh (control group)
Number of subjects: 58
Study 23335089 — intervention group
Group type: EXPERIMENTAL
Intervention: 1α-hydroxyvitamin D2 (1α‐OH‐D2)
Number of subjects: 0
Study 23335089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21741804 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hydrocortisone (100-140 mg)
Number of subjects: 25
Study 21741804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 18182271 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy monitoring (G2)
Number of subjects: 32
Study 18182271 — intervention group
Group type: COMPARATOR
Intervention: No entropy monitoring (G1)
Number of subjects: 32
Study 16679811 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laryngectomy
Number of subjects: 146
Study 16679811 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser microsurgical partial laryngectomy
Number of subjects: 146
Study 16679811 — intervention group
Group type: EXPERIMENTAL
Intervention: Open partial laryngectomy
Number of subjects: 146